Satraplatin 60215 GSK269962A

GSK269962A

Erlotinib HCl potently inhibits EGFR activation in intact cells including HNS human head and neck tumor cells (IC50 20nM)

123(12): 5298–5309

2017 May 15

The protein kinase C inhibitors Ro 318220 and GF 109203X are equally potent inhibitors of MAPKAP kinase-1beta (Rsk-2) and p70 S6 kinase

Satraplatin 60215 GSK269962ASatraplatin, also known as JM216 and BMS182751, is a platinum compound that is currently under investigation as one treatment of patients with advanced prostate cancer who have failed previous chemotherapy. It has not yet received approval from the U. S. Food and Drug Administration. First mentioned in the medical literature in 1993, satraplatin is the first orally active platinum based chemotherapeutic drug; other available platinum